Luis Borges - 02 Feb 2023 Form 4 Insider Report for Century Therapeutics, Inc. (IPSC)

Role: Chief Scientific Officer
Signature: /s/ Michael Diem, Attorney-in-Fact
Issuer symbol: IPSC
Transactions as of: 02 Feb 2023
Transactions value $: $0
Form type: 4
Filing time: 06 Feb 2023, 17:50:32 UTC
Previous filing: 27 Jan 2022
Next filing: 23 Mar 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IPSC	Common Stock	Award	$0	+21.9K		$0.00	21.9K	02 Feb 2023	Direct	F1
transaction	IPSC	Common Stock	Award	$0	+21.9K	+100%	$0.00	43.8K	02 Feb 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IPSC	Stock Option (right to buy)	Award	$0	+131K		$0.00	131K	02 Feb 2023	Common Stock	131K	$4.64	Direct	F2
transaction	IPSC	Stock Option (right to buy)	Award	$0	+131K		$0.00	131K	02 Feb 2023	Common Stock	131K	$4.64	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Century Therapeutic, Inc.'s (the "Company's") common stock. The RSUs vest 25% on February 2, 2024 and the remaining 75% vest on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Company's common stock.
F2	The option vests 25% on February 2, 2024, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service with the Issuer.

Content

Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Century Therapeutic, Inc.'s (the "Company's") common stock. The RSUs vest 25% on February 2, 2024 and the remaining 75% vest on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Company's common stock.

The option vests 25% on February 2, 2024, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service with the Issuer.